Our Patient and Product Registries Track Important Real World Information
Registries from Forian provide clinically relevant, richly detailed case information for a wide variety of patient groups under real world conditions. Our curated patient registries yield a richer understanding of disease progression, treatment protocol, therapeutic effectiveness — including alternative therapeutics such as cannabinoids and psychedelics — reported adverse events, product safety and efficacy, and quality of life measurements.
While clinical data can deliver quantitative outcome data, the importance and value of qualitative outcomes, such as patient quality of life, are increasingly required to understand true product efficacy, compliance, and value.
Patient-Reported Outcomes (PROs)
While clinical data can deliver quantitative outcome data, the importance and value of qualitative outcomes, such as patient quality of life, are increasingly required to understand true product efficacy, compliance, and value. Forian develops and fields custom, digital PROs data-capture applications. Whether gathered through email, text, or app-based PROs, measuring health from the patient’s perspective has powerful benefits and a wide variety of uses. PRO measures include important dimensions of the patient experience, including overall satisfaction, comfort, pain, and other more subjective measures of functional health status and wellbeing. These measurements uncover differences across various products, doses, and formulations to aid therapeutic decision-making.
Consequently, PROs are having a greater impact on healthcare product and treatment decisions by patients, providers, payers, and regulators, as well as by manufacturers of traditional and alternative therapies. PROs are particularly relevant for many of the conditions for which cannabinoid-based therapies are indicated, as those conditions often involve more subjective measures of functional health status and wellbeing.
Health Economics and Outcomes Research (HEOR)
Clinical benefits and costs of healthcare interventions are often hard to measure, especially when those benefits are experienced and valued by patients directly. Leveraging our proprietary Real World Data (RWD) and patient registries, Forian conducts rigorous research to provide evidence of clinical and economic value. Forian collaborates with clients and industry partners to quantify unmet real world needs, adherence, compliance, incidence, and prevalence, resource utilization and cost, as well as safety and effectiveness. The richness of Forian’s RWD, combined with the expertise and experience of our team, provide the ability to capture insights into the patient, caregiver, and provider experience, as well as evaluate the impact of policies on patient outcomes and predict which patients will benefit from new or different therapies.
Forian provides innovative software solutions, proprietary data, and predictive analytics to optimize the operational, clinical, and financial performance of our healthcare, cannabis, and government customers.